DXVX is showing strong performance. This is interpreted as being influenced by the news that the obesity treatment drug ‘Wegovy,’ which is gaining tremendous popularity in the United States this October, will be launched domestically.
As of 10:05 AM on the 13th, DXVX is trading at 3,300 KRW, up 2.17% compared to the previous day.
Wegovy is a once-weekly administered obesity treatment drug. Its main ingredient, GLP-1 glucagon-like peptide-1 receptor agonist, was initially approved for the treatment of type 2 diabetes. Recently, it has also been used for weight loss in people without diabetes.
In 2021, it was approved by the U.S. Food and Drug Administration (FDA) as an obesity treatment, and it has been called a game changer due to its effects surpassing existing obesity treatments. Elon Musk mentioned using it for his own weight loss, which even led to a sell-out situation.
Meanwhile, DXVX recently completed a patent application for an orally administered obesity treatment drug (GLP-1RA), a low-molecular GLP-1 receptor agonist developed in-house. It is characterized by overcoming the inconvenience of injection administration and high production costs, which were pointed out as drawbacks of existing peptide-based GLP-1RA treatments, and being designed for oral administration.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
